SCHEMBL1170146

SCHEMBL1170146

CN1CCC[C@H]1C(=O)OC(=O)[C@@H](N)CCC(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP8 Q6V1X1 6/20 0.43
DPP4 P27487 5/20 0.43
DPP9 Q86TI2 3/20 0.43
DPP7 Q9UHL4 2/20 0.43
FAP Q12884 1/20 0.43
ACE P12821 3/20 0.43
REN P00797 2/20 0.43
GRIN1 Q05586 2/20 0.37
GRIN2B Q13224 2/20 0.37
GRM8 O00222 1/20 0.37
GRM6 O15303 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GSR P00390 1/20 0.37
CYP1A2 P05177 1/20 0.37
GRIK1 P39086 1/20 0.37
GRM5 P41594 1/20 0.37
GRIA1 P42261 1/20 0.37
GRIA2 P42262 1/20 0.37
GRIA3 P42263 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1170142 0.90 PEPD (0.33) DPP8DPP4DPP9DPP7FAP
SCHEMBL3422835 0.75 DPP8 (0.45) DPP8DPP4DPP9DPP7FAP
SCHEMBL2719834 0.71 CYP3A4 (0.35) ACERENRAB9ACHRNB2CHRNA5
SCHEMBL4959221 0.71 GRM8 (0.62) DPP8DPP4DPP9GRIN1GRIN2B
SCHEMBL496858 0.71 GRM8 (0.62) DPP8DPP4DPP9GRIN1GRIN2B
SCHEMBL14645015 0.70 CYP3A4 (0.38) DPP8DPP4DPP7RAB9ACHRNB2
SCHEMBL30716624 0.70 QARS1 (0.40) DPP8DPP4DPP9DPP7FAP
Hydrochloric Acid SCHEMBL10636419 0.69 GRM8 (0.60) DPP8DPP4DPP9GRIN1GRIN2B
SCHEMBL11490824 0.69 FKBP1A (0.49)
SCHEMBL13601738 0.69 FKBP1A (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2001400-B1 ORAL FORMULATIONS OF GLYCYL-2-METHYLPROLYL-GLUTAMATE NEUREN PHARMACEUTICALS LTD (NZ) 2014-05-07 EP claimed
US-7887839-B2 microemulsions, water in oil emulsion, continuous hydrophobic phase including oil, surfactant; for treatment of neurodegenerative disorders; tablets; pharmacokinetics, bioavailability NEUREN PHARMACEUTICALS LTD. (NZ) 2011-02-15 US claimed
US-20090074865-A1 Oral formulations of glycyl-2-methylprolyl-glutamate NEUREN PHARMACEUTICALS LIMITED (AU) 2009-03-19 US claimed
EP-2001400-A2 ORAL FORMULATIONS OF GLYCYL-2-METHYLPROLYL-GLUTAMATE Neuren Pharmaceuticals Limited (NZ) 2008-12-17 EP claimed
WO-2007106555-A2 ORAL FORMULATIONS OF GLYCYL-2-METHYLPROLYL-GLUTAMATE NEUREN PHARMACEUTICALS LIMITED (NZ) 2007-09-20 WO claimed